Danish Construction Stock News

Why AL Sydbank is on investors’ radar today AL Sydbank (CPSE:ALSYDB) has drawn fresh attention after its recent share move, with the stock up 4.96% over the past day and modestly higher over the past week and month. See our latest analysis for AL Sydbank. That 1-day share price return of 4.96% comes after a softer year to date, with the share price return down 1.67%. Over the longer term, the 5-year total shareholder return of 369.28% points to strong historical rewards and suggests recent...

Carlsberg is preparing for a potential IPO of its India unit and has appointed major banks as advisers. The move would separate part of its India operations into a listed entity, subject to market conditions and internal approvals. The company has not yet announced a timetable or size for the potential offering. For investors tracking CPSE:CARL B, the India IPO preparation comes as the share price stands at DKK971.6. The stock is up 14.2% over the past 30 days, 17.7% year to date, and 12.3%...

Vestas Wind Systems (CPSE:VWS) has secured a major turbine order for RWE's 1,380 MW Vanguard West offshore wind project in the United Kingdom. The project adds a large UK offshore scheme to Vestas' order book and relates to a key part of the region's offshore wind pipeline. For you as an investor watching CPSE:VWS, this contract is closely linked to Vestas' core business of supplying wind turbines and related services. Offshore wind has been an area of policy focus in the UK, and government...

NKT (CPSE:NKT) reported record-high revenue and EBITDA, highlighting strong recent financial performance. The company launched its new corporate strategy, "Charging Forward", outlining its long term direction. Major capacity expansion projects are progressing, with operations expected to begin by 2027. NKT, a key supplier of power cable solutions, is positioned within grid and renewable energy infrastructure build outs. For investors tracking the energy transition, record revenue and EBITDA...

Novo Nordisk (CPSE:NOVO B) has entered a collaboration with Vivtex worth up to $2.1 billion to develop oral biologic therapies for obesity and diabetes. The partnership focuses on new oral delivery technologies that could make complex obesity and diabetes drugs easier for patients to take. Separately, Novo Nordisk reported a setback for its CagriSema obesity drug, which did not match Eli Lilly's Zepbound in late-stage trials. Novo Nordisk, trading at DKK238.4, is coming into this news after...

If you are wondering whether A.P. Møller - Mærsk is still good value after its recent run, this article will walk through what the current price might be telling you. The stock recently closed at DKK 15,620, with returns of 1.7% over 7 days, 8.4% over 30 days, 6.3% year to date, 30.5% over 1 year, 59.5% over 3 years and 118.9% over 5 years, which has many investors reassessing the risk and reward trade off. Recent headlines around A.P. Møller - Mærsk have focused on its role in global...

Why Danske Bank (CPSE:DANSKE) is on investors’ radar Danske Bank (CPSE:DANSKE) has drawn attention after recent share price moves, with the stock showing negative 1 day and past week returns but positive performance over the past month and past 3 months. See our latest analysis for Danske Bank. At a share price of DKK333.1, Danske Bank has seen short term share price weakness with a 1 day return of 2.5% decline and a 7 day return of 1.3% decline. However, the 1 month and 3 month share price...

Dampskibsselskabet Norden (CPSE:DNORD) has proposed amending its Articles of Association to reduce share capital by cancelling 1,000,000 treasury shares. This capital restructuring could influence how you think about the stock. See our latest analysis for Dampskibsselskabet Norden. The proposed DKK 1,000,000 share capital reduction comes as the share price sits at DKK283.0, with short term momentum reflected in a 4.1% 1 day and 12.1% 90 day share price return, while the 1 year total...

Why Vestas Wind Systems (CPSE:VWS) is on investors’ radar today Vestas Wind Systems (CPSE:VWS) is drawing fresh attention after a mixed recent run, with a roughly 12% decline over the past month contrasting with a gain of about 56% over the past year. See our latest analysis for Vestas Wind Systems. That mix of a 1-year total shareholder return of 55.7% and a 30-day share price return of an 11.7% decline suggests recent enthusiasm is cooling a little after a stronger run, as investors...

If you are wondering whether Aktieselskabet Schouw is priced attractively right now, this article walks through what the current share price might imply about its underlying value. The stock trades at DKK691.0, with returns of 3.3% over 30 days, 4.1% year to date, 20.4% over 1 year, 34.2% over 3 years, and 25.6% over 5 years. Recent performance is an important backdrop when thinking about value and risk. Recent coverage of Aktieselskabet Schouw has focused on providing investors with an up...

Why Novo Nordisk (CPSE:NOVO B) is on investors’ radar today Novo Nordisk (CPSE:NOVO B) has drawn fresh attention after recent share price weakness, with the stock showing negative returns over the past week, month, past 3 months, year to date and past year. See our latest analysis for Novo Nordisk. With the share price at DKK244.25, Novo Nordisk’s 30 day share price return of 39.14% and 1 year total shareholder return of 61.76% suggest momentum has faded recently compared with earlier gains...

If you are looking at Jyske Bank and wondering whether the current share price still offers value, the key question is how that price compares to what the business might reasonably be worth. The stock last closed at DKK 959.0, with returns of 2.4% over 7 days, 3.0% over 30 days, 9.3% year to date, 81.9% over 1 year, 79.2% over 3 years and 283.7% over 5 years. This naturally raises questions about what is already priced in and how risk is being perceived. These return figures have put Jyske...

If you are wondering whether Genmab shares offer fair value at current levels, this article will walk you through what the numbers are actually saying about the stock. Genmab's share price closed at DKK 1,832.5. This reflects a 2.1% decline over the last week, a 14.0% decline over the last month, an 8.7% decline year to date, and a 14.7% gain over the past year. Over 3 and 5 years, the returns are a 31.6% decline and a 14.8% decline respectively. Recent news coverage around Genmab has mainly...

FLSmidth (CPSE:FLS) has completed its shift into a pure-play mining technology provider following the divestment of its cement business. The company has appointed Toni Laaksonen as CEO and announced a reshaped Board, including a new proposed Chair and several departures. New executives have been named to lead key mining business lines, signaling an organizational reset around the mining portfolio. FLSmidth now trades as a focused mining technology and services company, with its...

A.P. Møller - Mærsk (CPSE:MAERSK B) has begun a DKK 6,300 million share buyback running over 12 months. The first phase targets both A and B shares and includes participation from major shareholder Familiefonden. See our latest analysis for A.P. Møller - Mærsk. The buyback comes as A.P. Møller - Mærsk’s share price has shown strong momentum over the past quarter, with a 90 day share price return of 24.48% and a 1 year total shareholder return of 32.60%. This suggests recent interest has been...

Methanex, Ørsted and Exolum have launched the U.K.’s first commercially ready biomethanol storage and marine bunkering service at the Port of Immingham, providing low‑carbon fuel for shipping and supporting Ørsted’s North Sea offshore wind maintenance vessels. The project shows how existing fuel infrastructure can be re‑tooled for green fuels, offering a practical pathway to cut domestic shipping emissions that currently exceed those from buses, trains and domestic aviation combined in the...

Zealand Pharma (CPSE:ZEAL) has drawn attention after reporting full year 2025 results, with sales of DKK 9,214.86 million and net income of DKK 6,455.01 million, compared to a net loss a year earlier. See our latest analysis for Zealand Pharma. Despite the strong full year 2025 results and recent trial update for ZP9830, the share price return has been weak over shorter periods, with a 30 day share price return showing a decline of 7.77% and a 1 year total shareholder return showing a decline...

Zealand Pharma reported positive topline Phase 1a data for Kv1.3 channel blocker ZP9830 from a single ascending dose trial. The study evaluated safety, tolerability, and pharmacological effects of ZP9830 in first in human testing. The company highlighted immunomodulatory potential based on the observed pharmacological effects in healthy volunteers. For Zealand Pharma, ticker CPSE:ZEAL, this update lands after a mixed share price record, with the stock at DKK382.8 and a 49.2% decline over...

Carlsberg triggered Carlsberg (CPSE:CARL B) has come into focus after a strong recent run in the share price, prompting investors to reassess how the brewer’s current valuation lines up with its fundamentals. See our latest analysis for Carlsberg. At a share price of DKK991.8, Carlsberg’s 30-day share price return of 17.26% and 90-day return of 29.41% suggest building momentum, while its 1-year total shareholder return of 20.83% points to solid medium term gains. If this kind of move has you...

GN Store Nord (CPSE:GN) shares have been reacting to the company’s full year 2025 earnings, in which both sales and net income were lower than the prior year. This has put renewed attention on the stock’s recent performance. See our latest analysis for GN Store Nord. The full year 2025 earnings release appears to have been a key catalyst for the share price, with the stock posting a 1 day share price return of 1.05% and a 7 day share price return of 1.45% after a softer 30 day share price...

Genmab (CPSE:GMAB) has wrapped up FY 2025 with fourth quarter revenue of US$1.1b and basic EPS of US$0.50, rounding out a trailing twelve month EPS of US$15.5 on revenue of US$3.7b. The company has seen quarterly revenue move from US$715 million in Q1 2025 to US$1.1b in Q4, alongside EPS ranging from US$3.06 in Q1 to US$6.51 in Q3 and US$0.50 in Q4. This sets up a results season where investors are likely to focus on how these shifts flow through to margins and the durability of its earnings...

NKT (CPSE:NKT) has drawn fresh attention after announcing an exclusive power cable partnership with German grid operator Mainova. The agreement runs to 2033 and supports Frankfurt’s long term electricity network upgrade and electrification needs. See our latest analysis for NKT. Alongside this Mainova deal and recent news such as the power purchase agreement with Uniper and the upcoming CFO change, NKT’s 1 year total shareholder return of 64.04% and 5 year total shareholder return of 264.59%...

Q1 earnings snapshot and why it matters for shareholders Coloplast (CPSE:COLO B) has just reported first quarter results, with sales of DKK 7,043 million, net income of DKK 1,397 million, and basic earnings per share of DKK 6.2 from continuing operations. See our latest analysis for Coloplast. At a share price of DKK485.0, Coloplast has seen a 30 day share price return of 10.65% decline and a year to date share price return of 9.58% decline, while the 1 year total shareholder return of 36.64%...

Genmab A/S has released its full-year 2025 results, reporting revenue of US$3.72 billion versus US$3.12 billion in 2024 and net income of US$963 million, alongside 2026 guidance calling for higher revenue but a potentially lower operating profit range of US$0.9–1.4 billion. The earnings update also highlighted FDA approval of Abkinley in second-line follicular lymphoma and a broadened oncology pipeline, including new Phase 3 trials and assets gained through acquisitions, which together...